The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2022 | Treating mesothelioma with checkpoint inhibitors
Paul Baas, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, describes the role of immune checkpoint inhibitors in treating mesothelioma. Current chemotherapy regimens are inadequate and provide limited efficacy, especially in non-epithelioid mesothelioma. Recent research has suggested that ipilimumab and nivolumab have demonstrated superior efficacy compared to standard chemotherapy in patients with mesothelioma. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.
Disclosures
Prof. Baas reports consultancy fees from BMS including research funding; all finances are for the hospital.
